Clinical Trial Update: Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab [Phase 4]

View source ↗

Summary

Phase 4 trial update describes patient preferences for combining everolimus with exemestane or capecitabine with bevacizumab in recurrent HER2-negative breast c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Capecitabine (capecitabine)
• Everolimus (everolimus)
• Exemestane (Exemestane)

Snippet

Sponsor: iOMEDICO AG | Conditions: Breast Cancer Recurrent, HER2/Neu-negative Carcinoma of Breast | Phase 4 | Status: COMPLETED